The main aim of the present study is to evaluate the clinical efficacy of first-line dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive acute lymphoblastic leukemia. In this study, the investigators will analyze the clinical outcomes for entire patient population as well as those for transplants, respectively. In addition, the results of this study will be compared to those of the investigators current study (imatinib plus conventional chemotherapy). The safety of this treatment will also be studied.
Name: Dasatinib
Description: After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeksType: DrugModified Hyper-CVAD + Dasatinib
Name: Cyclophosphamide
Description: 300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3Type: DrugModified Hyper-CVAD + Dasatinib
Name: Vincristine
Description: 1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 & 11Type: DrugModified Hyper-CVAD + Dasatinib
Name: Daunorubicin
Description: 45 mg/m2/day, IV for 1 hour, days 4 & 11Type: DrugModified Hyper-CVAD + Dasatinib
Name: Dexamethasone
Description: 40 mg/day, IV push, days 1-4 & days 11-14Type: DrugModified Hyper-CVAD + Dasatinib
Name: Cytarabine
Description: 2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5Type: DrugModified Hyper-CVAD + Dasatinib
Name: Mitoxantrone
Description: 12 mg/m2/day, IV for 30 minutes, days 1-2Type: DrugModified Hyper-CVAD + Dasatinib
Single Group Assignment
There is one SNP
Dasatinib, a potent dual BCR-ABL/SRC family kinase inhibitor, demonstrated 325-fold greater activity against native BCR-ABL compared with imatinib and has shown efficacy against all imatinib-resistant BCR-ABL mutations with the exception of T315I. --- T315I ---